Hospitals will lead thromboprophylactic drugs sales through 2036 with 61.8% of the end-user segment in 2026. The market was valued at USD 4.84 billion in 2025 and is expected to be worth USD 10.08 billion by 2036, creating an incremental opportunity of USD 4.91 billion between 2026 and 2036.